Daniella Lyustin

• MoCa Cognitive Assessment Certified Rater: 2024. Administering Institution: MoCa Cognition
• Advanced Clinical Research Coordinator Certification (ACRCC): 2022. Administering Institution: Certified Clinical Research Professionals Society (CCRPS)
• Good Clinical Practice Certification (GCP): 2021. Administering Institution: NIDA Clinical Trials Network
• C-SSRS Certification: 2021. Administering Institution: Research Foundation for Mental Hygiene

Psychiatric Consequences of Mild Traumatic Brain Injury. Diagnostic and Treatment Challenges. 

Bokarius, V., Jacobson, D., & Lyustin, D. (2024). Psychiatric consequences of mild traumatic brain injury. Diagnostic and treatment challenges. Directions in Psychiatry.

Alzheimer’s Disease: 

2021 - A multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (dextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer’s type, Phase III

Anxiety Disorders: 

2022 - A Phase 1b/2a Randomized, Double-Blind, Placebo Controlled, Parallel Study to Evaluate the Safety, Tolerability, and Efficacy of Two Doses of RLS103 (CBD Technosphere Inhalation Powder) in Subjects with Performance Anxiety within Social Anxiety Disorder (SAD), Phase I

2021 - A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of PH94B Nasal Spray for the Acute Treatment of Anxiety Induced by a Public Speaking Challenge in Adult Subjects with Social Anxiety Disorder, Phase III

2021 - A Phase 3 Open-label Safety Trial of PH94B Nasal Spray in the Acute Treatment of Anxiety in Adult Subjects with Social Anxiety Disorder (SAD), Phase III

Bipolar Disorder: 

2023- A Randomized, Stratified, Double-blind, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of JNJ-55308942 in Bipolar Depression.

Borderline Personality Disorder: 

2020 - A Multicenter, Randomized, Flexible-dose, Double-blind Trial of Brexpiprazole Versus Placebo for the Treatment of Adults With Borderline Personality Disorder, Phase II

2020 - A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Adult Subjects With Borderline Personality Disorder, Phase II

Major Depressive Disorder (MDD): 

2022 - A Double-Blind, Randomized, Parallel-Group Study with Quetiapine Extended Release as Comparator to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy, Phase III

2022 - A Phase III, multicentre, randomised, double-blind, placebo-controlled study to investigate the efficacy, safety, and tolerability of COMP360 in participants with treatment- resistant depression

2020 - A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole as Adjunctive Therapy in the Maintenance Treatment of Adults with Major Depressive Disorder. Otsuka. Phase III

2020 - A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants with Treatment-resistant Depression, Phase IV

2020 - Augmentation versus Switch: Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders with Treatment Resistant Depression (ASCERTAIN-TRD). Patient-Centered Outcomes Research Institute (PCORI). Phase IV.

Obsessive-Compulsive Disorder (OCD): 

2021 - A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Troriluzole, Phase III

2021 - A Multicenter, 48-week Open-Label Safety Study of Adjunctive Troriluzole in Subjects with Obsessive Compulsive Disorder, Phase III

Panic Disorder: 

2023 - A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Darigabat in Participants with Panic Disorder (ADAPT Trial)

Post-Traumatic Stress Disorder (PTSD): 

2021 - A 8-week-treatment, multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy, tolerability and safety of orally administered BI 1358894 in patients with Post-Traumatic Stress Disorder (PTSD), Phase II